Gilead Sciences CDR (GILD.CA) Stock Price, Forecast & Analysis
TSX:GILD
GILD.CA Key Statistics, Chart & Performance
The current stock price of GILD.CA is 29.34 CAD. In the past month the price increased by 4.15%.
GILD.CA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GILD.CA.
GILD.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to GILD.CA. While GILD.CA has a great profitability rating, there are some minor concerns on its financial health.
GILD.CA Financial Highlights
Over the last trailing twelve months GILD.CA reported a non-GAAP Earnings per Share(EPS) of 11.14. The EPS increased by 76.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.88% | ||
| ROA | 13.86% | ||
| ROE | 37.8% | ||
| Debt/Equity | 0 |
GILD.CA Forecast & Estimates
37 analysts have analysed GILD.CA and the average price target is 29.1 CAD. This implies a price decrease of -0.81% is expected in the next year compared to the current price of 29.34.
For the next year, analysts expect an EPS growth of 9.44% and a revenue growth 3.45% for GILD.CA
GILD.CA Ownership
GILD.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| EPRX | EUPRAXIA PHARMACEUTICALS INC | N/A | 583.286M | ||
| EDT | SPECTRAL MEDICAL INC | N/A | 397.882M | ||
| HBP | HELIX BIOPHARMA CORP | N/A | 150.469M | ||
| MDNA | MEDICENNA THERAPEUTICS CORP | N/A | 79.24M | ||
| COV | COVALON TECHNOLOGIES LTD | 13.18 | 52.478M | ||
| BCT | BRIACELL THERAPEUTICS CORP | N/A | 39.44M | ||
| MBX | MICROBIX BIOSYSTEMS INC | 5.94 | 33.252M | ||
| RVX | RESVERLOGIX CORP | N/A | 33.069M | ||
| HEM | HEMOSTEMIX INC | N/A | 17.573M | ||
| MPH | MEDICURE INC | N/A | 11.693M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About GILD.CA
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
Company Info
Gilead Sciences CDR
333 Lakeside Dr
Foster City CALIFORNIA US
Employees: 17600
Phone: 13026587581
Gilead Sciences CDR / GILD.CA FAQ
What does Gilead Sciences CDR do?
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
What is the current price of GILD stock?
The current stock price of GILD.CA is 29.34 CAD. The price decreased by -2.23% in the last trading session.
Does Gilead Sciences CDR pay dividends?
Gilead Sciences CDR (GILD.CA) has a dividend yield of 2.17%. The yearly dividend amount is currently 4.31.
How is the ChartMill rating for Gilead Sciences CDR?
GILD.CA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What sector and industry does Gilead Sciences CDR belong to?
Gilead Sciences CDR (GILD.CA) operates in the Health Care sector and the Biotechnology industry.
What is the expected growth for GILD stock?
The Revenue of Gilead Sciences CDR (GILD.CA) is expected to grow by 3.45% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for Gilead Sciences CDR?
Gilead Sciences CDR (GILD.CA) has a market capitalization of 36.40B CAD. This makes GILD.CA a Large Cap stock.